Characteristics of patients
| . | CB . | IB . | Anaplastic . | PMBL . | T-cell rich B cell . | DLBCL . | Total . | With IHC . | GCB . | Non-GCB . |
|---|---|---|---|---|---|---|---|---|---|---|
| All patients | n = 516 | n = 70 | n = 19 | n = 13 | n = 18 | n = 313 | n = 949 | n = 506 | n = 166 | n = 186 |
| Male | 267 51.7% | 46 65.7% | 9 47.4% | 5 38.5% | 13 72.2% | 171 54.6% | 511 53.8% | 268 53.0% | 85 51.2% | 102 54.8% |
| Female | 249 48.3% | 24 34.3% | 10 52.6% | 8 61.5% | 5 27.8% | 142 45.4% | 438 46.2% | 238 47.0% | 81 48.8% | 84 45.2% |
| Median age, y (range) | 69 (61-80) | 71 (61-79) | 67 (62-74) | 68 (62-79) | 69 (61-77) | 68 (61-80) | 69 (61-80) | 68 (61-80) | 69 (61-80) | 69 (61-80) |
| IPI factors | ||||||||||
| Age older than 60 y | 516 100.0% | 70 100.0% | 19 100.0% | 13 100.0% | 18 100.0% | 313 100.0% | 949 100.0% | 506 100.0% | 166 100.0% | 186 100.0% |
| LDH > UNV | 239 46.3% | 40 57.1% | 12 63.2% | 10 76.9% | 9 50.0% | 157 50.2% | 467 49.2% | 231 45.7% | 67 40.4% | 92 49.5% |
| ECOG > 1 | 64 12.4% | 12 17.1% | 1 5.3% | 3 23.1% | 2 11.1% | 52 16.6% | 134 14.1% | 62 12.3% | 17 10.2% | 27 14.5% |
| Stage III/IV | 242 46.9% | 37 52.9% | 5 26.3% | 7 53.8% | 10 55.6% | 161 51.4% | 462 48.7% | 222 43.9% | 61 36.7% | 92 49.5% |
| E > 1 | 87 16.9% | 14 20.0% | 3 15.8% | 3 23.1% | 1 5.6% | 63 20.1% | 171 18.0% | 73 14.4% | 17 10.2% | 34 18.3% |
| IPI score | ||||||||||
| 1 | 174 33.7% | 18 25.7% | 6 31.6% | 2 15.4% | 5 27.8% | 95 30.4% | 300 31.6% | 181 35.8% | 71 42.8% | 56 30.1% |
| 2 | 136 26.4% | 19 27.1% | 7 36.8% | 4 30.8% | 6 33.3% | 86 27.5% | 258 27.2% | 141 27.9% | 43 25.9% | 54 29.0% |
| 3 | 136 26.4% | 20 28.6% | 4 21.1% | 4 30.8% | 5 27.8% | 66 21.1% | 235 24.8% | 118 23.3% | 39 23.5% | 43 23.1% |
| 4,5 | 70 13.6% | 13 18.6% | 2 10.5% | 3 23.1% | 2 11.1% | 66 21.1% | 156 16.4% | 66 13.0% | 13 7.8% | 33 17.7% |
| Bulky disease | 186 36.0% | 33 47.1% | 6 31.6% | 5 38.5% | 7 38.9% | 115 36.7% | 352 37.1% | 174 34.4% | 58 34.9% | 63 33.9% |
| B-symptoms | 159 30.8% | 26 37.1% | 4 21.1% | 7 53.8% | 8 44.4% | 108 34.5% | 312 32.9% | 154 30.4% | 48 28.9% | 60 32.3% |
| E-involvement | 280 54.3% | 44 62.9% | 7 36.8% | 7 53.8% | 3 16.7% | 202 64.5% | 543 57.2% | 267 52.8% | 75 45.2% | 100 53.8% |
| BM involvement | 23 4.5% | 5 7.1% | 0 0.0% | 0 0.0% | 0 0.0% | 24 7.7% | 52 5.5% | 26 5.1% | 6 3.6% | 11 5.9% |
| . | CB . | IB . | Anaplastic . | PMBL . | T-cell rich B cell . | DLBCL . | Total . | With IHC . | GCB . | Non-GCB . |
|---|---|---|---|---|---|---|---|---|---|---|
| All patients | n = 516 | n = 70 | n = 19 | n = 13 | n = 18 | n = 313 | n = 949 | n = 506 | n = 166 | n = 186 |
| Male | 267 51.7% | 46 65.7% | 9 47.4% | 5 38.5% | 13 72.2% | 171 54.6% | 511 53.8% | 268 53.0% | 85 51.2% | 102 54.8% |
| Female | 249 48.3% | 24 34.3% | 10 52.6% | 8 61.5% | 5 27.8% | 142 45.4% | 438 46.2% | 238 47.0% | 81 48.8% | 84 45.2% |
| Median age, y (range) | 69 (61-80) | 71 (61-79) | 67 (62-74) | 68 (62-79) | 69 (61-77) | 68 (61-80) | 69 (61-80) | 68 (61-80) | 69 (61-80) | 69 (61-80) |
| IPI factors | ||||||||||
| Age older than 60 y | 516 100.0% | 70 100.0% | 19 100.0% | 13 100.0% | 18 100.0% | 313 100.0% | 949 100.0% | 506 100.0% | 166 100.0% | 186 100.0% |
| LDH > UNV | 239 46.3% | 40 57.1% | 12 63.2% | 10 76.9% | 9 50.0% | 157 50.2% | 467 49.2% | 231 45.7% | 67 40.4% | 92 49.5% |
| ECOG > 1 | 64 12.4% | 12 17.1% | 1 5.3% | 3 23.1% | 2 11.1% | 52 16.6% | 134 14.1% | 62 12.3% | 17 10.2% | 27 14.5% |
| Stage III/IV | 242 46.9% | 37 52.9% | 5 26.3% | 7 53.8% | 10 55.6% | 161 51.4% | 462 48.7% | 222 43.9% | 61 36.7% | 92 49.5% |
| E > 1 | 87 16.9% | 14 20.0% | 3 15.8% | 3 23.1% | 1 5.6% | 63 20.1% | 171 18.0% | 73 14.4% | 17 10.2% | 34 18.3% |
| IPI score | ||||||||||
| 1 | 174 33.7% | 18 25.7% | 6 31.6% | 2 15.4% | 5 27.8% | 95 30.4% | 300 31.6% | 181 35.8% | 71 42.8% | 56 30.1% |
| 2 | 136 26.4% | 19 27.1% | 7 36.8% | 4 30.8% | 6 33.3% | 86 27.5% | 258 27.2% | 141 27.9% | 43 25.9% | 54 29.0% |
| 3 | 136 26.4% | 20 28.6% | 4 21.1% | 4 30.8% | 5 27.8% | 66 21.1% | 235 24.8% | 118 23.3% | 39 23.5% | 43 23.1% |
| 4,5 | 70 13.6% | 13 18.6% | 2 10.5% | 3 23.1% | 2 11.1% | 66 21.1% | 156 16.4% | 66 13.0% | 13 7.8% | 33 17.7% |
| Bulky disease | 186 36.0% | 33 47.1% | 6 31.6% | 5 38.5% | 7 38.9% | 115 36.7% | 352 37.1% | 174 34.4% | 58 34.9% | 63 33.9% |
| B-symptoms | 159 30.8% | 26 37.1% | 4 21.1% | 7 53.8% | 8 44.4% | 108 34.5% | 312 32.9% | 154 30.4% | 48 28.9% | 60 32.3% |
| E-involvement | 280 54.3% | 44 62.9% | 7 36.8% | 7 53.8% | 3 16.7% | 202 64.5% | 543 57.2% | 267 52.8% | 75 45.2% | 100 53.8% |
| BM involvement | 23 4.5% | 5 7.1% | 0 0.0% | 0 0.0% | 0 0.0% | 24 7.7% | 52 5.5% | 26 5.1% | 6 3.6% | 11 5.9% |